tbuckley/cabot-search huggingface dataset:
Abstract 20701: Genetics or Environment - The First Twin Study of Coronary Endothelial Shear Stress
Authors: Ernest Lo, Márton Kolossváry, Kush Patel, Zsófia Drobni, Pieter Kitslaar, Johan H Reiber, Leon Menezes, Francesca Pugliese, Mark Westwood, Ádám D Tárnoki, Júlia Karády, Szilárd Vörös, Béla Merkely, Christos V Bourantas, Ryo Torii, Pál Maurovich-Horvat
Journal: Circulation (2017)

Introduction: There is a robust evidence to show a genetic disposition in the development of coronary artery disease. Several twin studies have examined the association between systemic risk factors such as hypertension or hypercholesterolemia and heritability but there is no previous work concerning the effect of genetics on local intracoronary hemodynamic forces. Hypothesis: Investigation of the heritability of endothelial shear stress (ESS) across the coronary artery systems of twins will shed light on the relative contribution of genetics and biomechanical factors (environment) to local coronary atherosclerotic lesions. Methods: Coronary CT angiograms were acquired from 10 twin pairs: 6 monozygotic (MZ) and 4 dizygotic (DZ). In the acquired images, the lumen borders were segmented in the main epicardial arteries and their side branches. The annotated borders were used to reconstruct coronary anatomy and estimate the ESS using computational fluid dynamics. The flow conditions of simulations were person...
Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study
Authors: Alessandra Larocca, Marco Salvini, Lorenzo De Paoli, Nicola Cascavilla, Giulia Benevolo, Monica Galli, Vittorio Montefusco, Tommaso Caravita di Toritto, Anna Baraldi, Stefano Spada, Nicola Giuliani, Chiara Pautasso, Stefano Pulini, Sonia Ronconi, Norbert Pescosta, Anna Marina Liberati, Francesca Patriarca, Claudia Cellini, Patrizia Tosi, Massimo Offidani, Michele Cavo, Antonio Palumbo, Mario Boccadoro, Sara Bringhen
Journal: Blood (2018)
Aberrations of BUBR1 expression and <i>TP53</i> gene in human colorectal cancer.
Authors: Koji Ando, Eiji Oki, Zhao Yan, Hiroyuki Kawano, Yukiharu Hiyoshi, Shuhei Ito, Eriko Tokunaga, Hiroshi Saeki, Masaru Morita, Yoshihiko Maehara
Journal: Journal of Clinical Oncology (2014)

e14578 Background: Defects in mitotic checkpoint and p53-dependent pathways are associated with chromosomal instability. Recent studies demonstrated functional connections between the spindle assembly checkpoint protein BUBR1 and p53. However, the interplay between BUBR1 and p53 and their association with genetic instability has not been well investigated. In this study we evaluated the BUBR1 expression and TP53gene to reveal the association between these two molecules. Methods: There were139 colorectal cases examined for BUBR1 expression, TP53 gene and genetic instability indicators. BUBR1 expression was evaluated by immunohistochemistry and the TP53 gene was directly sequenced. DNA ploidy was studied by laser scanning cytometry; microsatellite instability (MSI) was examined by dual-fluorescent based fragment analysis. Results: BUBR1 aberrant expression; high expression, was detected in 64.7% cases. High BUBR1 expression was associated with TP53 mutation (P=0.017). High BUBR1 expression and TP53 mutation were associated with DNA aneuploidy (P=0.05, P=0.011, respectively), and showed an inverse association with microsatellite instability (P=0.09, P=0.0005). Because of the important roles of both BUBR1 and TP53 gene in maintaining chromosomal homeostasis, we examined potential correlations of both BUBR1 and TP53 gene with genetic instability. Cases were categorized into three groups according to the status of BUBR1 and TP53 gene. Both high BUBR1 expression and TP53 gene mutation were found in 28.1% cases; either BUBR1 or TP53 gene aberration was confirmed in 25.2%; and the remaining 46.8% showed neither of the aberrations. These three groups were accordingly named “Both,” “Either,” and “Neither.” The “Both” group had a more profound chromosomal instability phenotype compared to the “Neither” group (P=0.005). The “Either” group had a moderate aneuploidy ratio. The “Neither” group showed a higher MSI (+) ratio (26.1%) than the “Either” (5.7%) or “Both” group (2.5%) (P = 0.027 and P< 0.001, respectively). Conclusions: Our findings indicated interplay between BUBR1 and p53 in colorectal cancer. Altered expression of both molecules cooperatively associated with chromosomal instability, which may be important in colorectal cancer development.
In-vitro corrosion of AZ31 magnesium alloys by using a polydopamine coating
Authors: Anna Carangelo, Annalisa Acquesta, Tullio Monetta
Journal: Bioactive Materials (2018)

Magnesium alloys are candidates to be used as biodegradable biomaterials for producing medical device. Their use is restricted due to the high degradation rate in physiological media. To contribute to solving this problem, a polydopamine (PDOPA) layer could be used to increase adhesion between the metallic substrate and external organic coating. In this paper, the corrosion behaviour of samples was investigated to determine their performance during the long-term exposure in simulated body fluid. Electrochemical methods including Open Circuit Potential (OCP) and Electrochemical Impedance Spectroscopy (EIS) were used to investigate the corrosion resistance of samples. The results demonstrated a decreasing of the substrate degradation rate when PDOPA was used as interlayer supposing a synergistic effect when it was used together with the organic coating.
Why Pregnant Women May Justifiably Choose to Use Cannabis
Authors: Kevin M. Takakuwa, Raquel M. Schears
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Accrual of adolescents and young adults with cancer to eligible clinical trials: A report from the NCIC Clinical Trials Group (NCIC-CTG).
Authors: Lesleigh S. Abbott, Annette E. Hay, Corey Willman, Alison Urton, Joseph L Pater, Janet Dancey, Elizabeth A. Eisenhauer, Lesley Seymour
Journal: Journal of Clinical Oncology (2014)

6543 Background: Improvement in 5-year survival among adolescents and young adults with cancer (AYAWC) has not kept pace with gains made in other age groups. Further, in the United States, 40-70% of children younger than 15 years old are enrolled onto National Cancer Institute clinical trials while less than 2% of 20-29 year old participated (Burke et al. 2007; Bleyer et al. 2002; 2006). We hypothesized that AYAWC were also underrepresented on clinical trials performed through the NCIC CTG, a predominantly adult oncology group. Methods: For this analysis, we defined AYAWC as 15-29 years old. All relevant trials from 2003-2013 were reviewed. Canadian cancer incidence was obtained from the Canadian Cancer Statistics (CCS) registry, deriving the mean annual incidence from data collected over a three year period (Statistics Canada, 2005-2007). We assessed the ratio of the number of AYA enrolled in NCIC CTG trials over the average annual numbers of new cases of the cancers in the AYA population in Canada and the ratio of the total numbers of patients on the NCIC CTG trials over average new cases of the cancer. Results: A total of 24,044 patients were enrolled on NCIC CTG trials, including 159 AYAWC (0.66%), while AYAWC represented 1.6% of incident cases from 2005-2007. The table indicates a selection of key AYA cancers; however, the total represents all cancer types included in this study. Conclusions: Overall AYA patients are more than 2-fold under-represented in current adult clinical trials; however, certain cancer types such as colorectal, breast and non-Hodgkin lymphoma have better than expected accrual as compared to incidence data. Disease CCS incidence NCIC CTG accrual Accrued/incidence (%) Total AYAWC Total AYAWC Total AYAWC Leukemia 1,206 97 372 6 31 6 Breast 20,757 93 10,509 60 51 64 Colorectal 20,043 44 3,244 12 16 27 Lung 22,562 27 4,460 2 20 7 Hodgkin 856 285 223 17 26 6 Non-Hodgkin 6,511 146 1,115 41 17 28 Total 104,314 1,480 24,044 159 23 11
Mortality from malignant bowel obstruction in hospitalized U.S. cancer patients.
Authors: Olatunji Boladale Alese, Sungjin Kim, Zhengjia Chen, Taofeek Kunle Owonikoko, Bassel F. El-Rayes
Journal: Journal of Clinical Oncology (2014)

9626 Background: Malignant bowel obstruction (MBO) affects an estimated 3 - 15% of cancer patients globally, with a mean survival rate no longer than 4 weeks in inoperable MBO. We assessed predictors of survival and the influence of treatment modality in hospitalized MBO patients in the US. Methods: Data were obtained from all US states that contributed to the Nationwide Inpatient Sample (NIS) by Agency for Health Care Research and Quality in 2006 and 2010. MBO diagnoses and treatment variables were identified using Clinical Classification Software code based on ICD9 and CPT codes. Univariate and multivariate analyses were performed with a logistic model, weighted chi-square test, and a generalized linear model with the use of generalized estimated equation. Initial analysis in the 2006 NIS data was validated in the 2010 NIS data. Results: 942,014 and 1,103,528 eligible MBO patients were identified in 2006 and 2010 respectively. The in-hospital mortality was 24.5% in 2006, decreasing to 21.4% by 2010. The commonest concurrent condition was chronic lung disease (20.4%). Medical management (vs. surgical management), health insurance coverage, and obesity were significantly associated with better hospital survival in MBO patients. Adjusted analysis showed significantly increased odds of death with male gender, older age, stage IV disease, multiple co-morbid conditions (except obesity and AIDS) and weight loss. Conclusions: Lack of insurance coverage, weight loss and surgical management are associated with higher mortality in hospitalized MBO patients. Multivariable analysis of in-hospital mortality in 2010 (with covariates found significant in 2006). Covariate Level Died during hospitalization Relative risk 95%CI P-value Management Medical 0.78 0.72 - 0.86 <.001 Surgical 1 (Ref) - - Insurance status Insured 0.63 0.48 – 0.82 <.001 Noninsured 1 (Ref) - - Metastasis Present 1.65 1.52 – 1.78 <.001 Absent 1 (Ref) - - Weight loss Present 1.49 1.36 – 1.63 <.001 Absent 1 (Ref) - - Obesity Present 0.46 0.39 – 0.55 <.001 Absent 1 (Ref) - -
Cabazitaxel in patients with refractory recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Results of phase II trial unicancer ORL03.
Authors: Jerome Fayette, Joel Guigay, Christophe Le Tourneau, Marian Degardin, Frederic Peyrade, Florence Orlandini, Karine Buffard, Carine A. Bellera
Journal: Journal of Clinical Oncology (2014)

e17028 Background: After failure of platinum, anti-EGFR and taxanes R/M SCCHN patients (pts) are considered ‘refractory’ and methotrexate is the only option as palliative care. Cabatizaxel prolongs survival in hormone - refractory metastatic prostate cancer after failure of docetaxel. Could it be effective for refractory R/M SCCHN pts? Methods: To be included in this multicentre, phase II study, pts required to be progressive after platinum, cetuximab and taxanes (sequential and with various combinations) and to have PS 0-2. Cabazitaxel was given at 25 mg/m² every 3 weeks (wks) for a maximum of 10 cycles. G-CSF support with lenograstim 150 μg/m²/day was delivered after each cycle of chemotherapy. Response was assessed every 6 wks, according to RECIST 1.1 (centralized review). The primary endpoint was non-progression at 6 weeks. A two-stage Simon optimal design was chosen (P0=0.10; P1=0.30) and 29 evaluable pts were required. To accrue the second stage 2/10 non-progressions were needed. A total of 6 non-progressions or more were required in order to make the drug worthy of further study. Planned interim analysis results are provided below. Results: Thirty one pts have been enrolled, 29 were eligible: 22 males, median age 60 years (30-71), 13 (45%) oropharynx, 2 (7%) metastatic. All received at least 2 previous lines of chemotherapy and cetuximab. Twenty nine pts were evaluable for the primary end point: 21 were progressive and 8 (27.6%; 95%CI 12.7%-47.2%) had Stable Disease. Fifteen pts had severe treatment-related adverse events, with febrile neutropenia in 6 pts /31, 1 death) The main grade 3-4 toxicity was neutropenia with 7 pts (21%) having at least one event. Conclusions: Cabazitaxel met its primary endpoint with a 27.6% disease control rate at 6 weeks in heavily pretreated refractory R/M SCCHN pts. Tolerability seems to be acceptable in such a population usually in poor medical condition. Clinical trial information: NCT01620242.
Quality of life after stereotactic hypofractionated radiotherapy for prostate cancer patients.
Authors: Monika Rucinska, Anna Kieszkowska-Grudny, Wojciech Strzelczyk, Katarzyna Bielesz, Sergiusz Nawrocki
Journal: Journal of Clinical Oncology (2014)

e16089 Background: The standard treatment for early stage of prostate cancer is operation or radiotherapy. The objective of the study was to investigate safety of stereotactic hypofractionated radiotherapy for localized prostate cancer and the quality of life (QoL) after treatment. Methods: A prospective one-center clinical study was done on prostate cancer patients with localized low- and intermediate-risk (according to NCCN) adenocarcinoma of prostate T2a-T2cN0M0. Patients received 33.5Gy in 5 fractions twice a week (with X ray from accelerator), which is equivalent to conventional 78Gy in 39 fractions a 2Gy (α/β for prostate cancer 1,4Gy). Acute and late toxicity (according to RTOG/EORTC) were estimated during radiotherapy and every 3 months after the end of treatment. Subjects filled out questionnaires EORTC QLQ-C30 and QLQ-PR25. Results: This analysis included 40 men (age: 55-83 years, mean 72, median 73; PSA 5.6-20ng/ml, mean 10.9, median 9.9; Gleason score 5-7, mean and median 6). Evaluations of QoL were performed minimum 9 months after radiotherapy (mean and median 11.5 months). The tolerance of treatment was good. 57.5% of patients did not develop any acute reaction, no Grade 3 or higher acute and late toxicity was reported (according to RTOG/EORTC). More that 80% of patients assessed their general health and general QoL as 5 and better (on 7-points scale). Up to 80% of men felt that as a result of illness or treatment has lost masculinity, however 65% of patients after radiotherapy are still interested in having sex, 38% of them were sexually active and 30% felt satisfaction with sex life. Overall QoL was negatively correlated with education, physical, emotional, cognitive and social functioning, fatigue, pain, dyspnea, insomnia, loss of appetite, constipation, and in general disease symptoms, but also financial situation. However, non predictor of high QoL was found within demographic and medical factors. Conclusions: Stereotactic hypofractionated radiotherapy for prostate cancer patients is a safe treatment in relation to toxicity and patients' QoL assessment in short term analysis. The extended follow-up is needed.
Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis
Authors: Jérémy Magalon, Mélanie Velier, Stéphanie Simoncini, Pauline François, Baptiste Bertrand, Aurélie Daumas, Audrey Benyamine, Romain Boissier, Laurent Arnaud, Luc Lyonnet, Samantha Fernandez, Françoise Dignat-George, Dominique Casanova, Benjamin Guillet, Brigitte Granel, Pascale Paul, Florence Sabatier
Journal: Annals of the Rheumatic Diseases (2019)

The autologous stromal vascular fraction (SVF) from adipose tissue is an alternative to cultured adipose-derived stem cells for use in regenerative medicine and represents a promising therapy for vasculopathy and hand disability in systemic sclerosis (SSc). However, the bioactivity of autologous SVF is not documented in this disease context. This study aimed to compare the molecular and functional profiles of the SVF-based medicinal product obtained from SSc and healthy subjects.Good manufacturing practice (GMP)-grade SVF from 24 patients with SSc and 12 healthy donors (HD) was analysed by flow cytometry to compare the distribution of the CD45- and CD45+ haematopoietic cell subsets. The ability of SVF to form a vascular network was assessed using Matrigel in vivo assay. The transcriptomic and secretory profiles of the SSc-SVF were assessed by RNA sequencing and multiplex analysis, respectively, and were compared with the HD-SVF.The distribution of the leucocyte, endothelial, stromal, pericyte and transitional cell subsets was similar for SSc-SVF and HD-SVF. SSc-SVF retained its vasculogenic capacity, but the density of neovessels formed in SVF-loaded Matrigel implanted in nude mice was slightly decreased compared with HD-SVF. SSc-SVF displayed a differential molecular signature reflecting deregulation of angiogenesis, endothelial activation and fibrosis.Our study provides the first evidence that SSc does not compromise the vascular repair capacity of SVF, supporting its use as an innovative autologous biotherapy. The characterisation of the specific SSc-SVF molecular profile provides new perspectives for delineating markers of the potency of SVF and its targets for the treatment of SSc.
Abstract 17087: Novel Trauma Work Flow Using IVR-CT Installed in Trauma Resuscitation Room Improved Mortality in Patients With Severe Torso Injury
Authors: Takahiro Kinoshita, Kazuma Yamakawa, Hiroki Matsuda, Naoki Nakamoto, Jumpei Yoshimura, Atsushi Watanabe, Satoshi Fujimi
Journal: Circulation (2017)

Introduction: In August 2011, an interventional radiology - computed tomography (CT) system was installed in our trauma resuscitation room. We named it the Hybrid emergency room (ER) as it enabled ...
Longitudinal assessment of general health-related QOL in patients undergoing active surveillance (AS) for low-risk prostate cancer: Interim results of the PRIAS-JAPAN cohorts.
Authors: Mikio Sugimoto, Hiromi Hirama, Yoshiyuki Kakehi
Journal: Journal of Clinical Oncology (2014)

5057 Background: Japan is participating in the Prostate cancer Research International: Active Surveillance (PRIAS) study as PRIAS-JAPAN since 2010. QOL has been assessed annually as an independent side study of PRIAS-JAPAN. The objective of this study is to measure the base-line QOL and the longitudinal changes in QOL status of Japanese AS cohorts. Methods: PRIAS-JAPAN study was launched since January 2010. Until July 2013, 354 patients were enrolled into the study from 33 institutions. Participants’ general health related QOL (HRQOL) have been assessed using SF-8 at enrollment and annually thereafter. QOL subscales and summary scores were compared with norm-based scoring (general population) and also between each evaluation points over time. A paired t-test served to compare the data, and p< 0.05 was considered to indicate statistical significance. Results: Of the 354, 325 could be able to follow in PRIAS protocol. Median age of participants was 68 (45-87 yr.), median PSA was 5.27ng/ml (1.5-9.93). 220 patients were remained on the AS program with median observation period of 15 months. Of the 325 patients, QOL was evaluable in 315, 183, 48 and 18 patients at enrollment, 1-year, 2-year and 3-year after, respectively. Almost all domains of QOL at enrollment revealed better QOL than that of general population. At 1 and 2-year after starting of AS, there was no significant QOL deterioration and favorable QOL was maintained. When it stratified by median baseline QOL score, the physical and mental component summary score in favorable baseline QOL group were deteriorated over time (p<0.01 and p<0.05 respectively). On the other hand, those of unfavorable baseline QOL group revealed significant improvements over time (p<0.05 and p<0.01 respectively). Conclusions: QOL of the Japanese patients who choose AS as initial treatment is relatively better than that in general population and it has been maintained at 2-year after AS. However, there is a possibility of QOL deterioration with time, especially for better QOL patients at baseline. Clinical trial information: UMIN000009876.
A new look at the IDEA classification: Defining novel predictive and prognostic markers in stage III colon cancer.
Authors: Ofer Margalit, Ronac Mamtani, Yu-Xiao Yang, Kim Anna Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce J. Giantonio, Einat Shacham-Shmueli, Shimon Ben Boursi
Journal: Journal of Clinical Oncology (2018)

845 Background: The IDEA pooled analysis compared 3 to 6 months of adjuvant chemotherapy for newly defined low- and high-risk stage III colon cancer patients, suggesting low-risk patients may be offered only 3 months of treatment. We aimed to evaluate the benefit of monotherapy vs doublet chemotherapy in low and high IDEA risk groups. Methods: Using the NCDB (2004-2014) we identified 56,728 and 47,557 individuals as low and high IDEA risk groups, respectively. We used multivariate COX regression to evaluate the magnitude of survival differences between IDEA risk groups, according to treatment intensity (doublet vs monotherapy). In a secondary analysis, we examined the predictive value of subgroups of age. Results: Low and high IDEA risk groups derived similar benefit from doublet chemotherapy compared to monotherapy, with hazard ratios of 0.83 (95%CI 0.79-0.86) and 0.80 (95%CI 0.78-0.83), respectively. The only subpopulations that did not benefit from doublet chemotherapy were low-risk patients above the age of 72 (HR = 0.95, 95%CI 0.90-1.01) and high-risk patients above the age of 85 (HR = 0.90, 95%CI 0.77-1.05). Conclusions: IDEA risk classification does not predict benefit from doublet chemotherapy in stage III colon cancer. However, omission of oxaliplatin can be considered in IDEA low-risk patients above the age of 72.